Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Anakinra for Postprandial Hypoglycemia in Prediabetes
NCT05174507Phase 2Withdrawn
- Sponsor
- University Hospital Basel
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin and anakinra in postprandial hypoglycemia, sponsored by University Hospital Basel. Planned start Jun 2022; status: withdrawn.
02
Drugs
empagliflozinanakinra
03
Conditions
postprandial hypoglycemia
Beyond the preview
Go deeper on NCT05174507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174507.